OrbiMed Capital GP VII LLC

10% Owner | Director

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001760648

Purchase history

Companies traded: 4
Purchases · 12M: 3
Purchases · 24M: 4
Average purchase: $13.3M
Median purchase: $15.6M
Gross purchase value: $53.2M

Companies: ADARx Pharmaceuticals, Inc. | Electra Therapeutics, Inc. | MBX Biosciences, Inc. | Q32 Bio Inc.

4 SEC accession(s) · 4 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

Published	Company	Ticker	Role	Reported value	SEC source
2026-09-30	ADARx Pharmaceuticals, Inc.	ADRX	Director \| 10% Owner	$16.1M	Open filing
2026-09-23	Electra Therapeutics, Inc.	ETRA	Director \| 10% Owner	$20.0M	Open filing
2026-06-01	Q32 Bio Inc.	QTTB	Director \| 10% Owner	$15.0M	Open filing
2025-02-19	MBX Biosciences, Inc.	MBX	Director \| 10% Owner	$2.0M	Open filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	3Small Sample	75.0% (3/4)	33.3% (1/3)	-10.5%	-6.6%	-15.0%
20D	1Small Sample	50.0% (1/2)	100.0% (1/1)	+10.6%	+10.6%	+10.6%
60D	1Small Sample	50.0% (1/2)	100.0% (1/1)	+37.5%	+37.5%	+37.5%
120D	0No Data	0.0% (0/1)	—	—	—	—

Research patterns

First purchase in 12M: 3/3
Large purchase ≥ $100k: 4/4
Cluster buying · 15D: 4/4
Buying the dip: 0/1

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.